Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Kausik Ray Articles

VIDEO: Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?

Posted on 16 March 2018 | Posted by Kausik Ray | Posted in Videos, 67th Annual Scientific Sessions of the American College of Cardiology 2018

ESC Congress 2017: CANTOS shows it’s not all about lipids

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study (1) showed that treatment with canakinumab, an inhibitor of interleukin-1β (IL-1β), reduced the risk of major adverse cardiovascular events. Lead author, Professor Paul Ridker (Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, USA) compared…

Posted on 31 August 2017 | Posted by Kausik Ray | Posted in European Society of Cardiology Congress 2017

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters